Compile Data Set for Download or QSAR
maximum 50k data
Found 2784 Enz. Inhib. hit(s) with Target = 'Plasminogen'
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50120225(2-{[2-(4-Guanidino-butyrylamino)-3-(4-nitro-phenyl...)
Affinity DataIC50:  0.230nMAssay Description:Concentration of the compound required to inhibit Plasmin was determinedMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514073(CHEMBL4576519)
Affinity DataIC50:  0.320nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514076(CHEMBL4456691)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514062(CHEMBL4436082)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514063(CHEMBL4447001)
Affinity DataIC50:  0.420nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514065(CHEMBL4570952)
Affinity DataIC50:  0.800nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514079(CHEMBL4449958)
Affinity DataIC50:  0.870nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514077(CHEMBL4475211)
Affinity DataIC50:  1nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514078(CHEMBL4582882)
Affinity DataIC50:  2.10nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen activator inhibitor 1(Homo sapiens (Human))
University Of Michigan

LigandPNGBDBM92479(Tannic Acid, A | Tannic acid)
Affinity DataIC50:  7nMpH: 7.8 T: 2°CAssay Description:Enzyme activity assay using human and murine PAI-1.More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50514075(CHEMBL4541084)
Affinity DataIC50:  8.60nMAssay Description:Inhibition of human plasmin preincubated for 15 mins followed by MeOSuc-Ala-Phe-Lys-AMC substrate addition and measured after 30 mins by fluorescence...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50029498(1N-[2-{2-[4-amino(imino)methylamino-1-formyl-(1S)-...)
Affinity DataIC50:  9.60nMAssay Description:In vitro Enzyme Inhibitory activity measured against PlasminMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen activator inhibitor 1(Homo sapiens (Human))
University Of Michigan

LigandPNGBDBM175526(US9120744, CDE-002)
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:To determine the efficacy of various synthesized PAI-1 inhibitor compounds, a fluorometric plate assay was carried out to measure the half maximal in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen activator inhibitor 1(Homo sapiens (Human))
University Of Michigan

LigandPNGBDBM175527(US9120744, CDE-003)
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:To determine the efficacy of various synthesized PAI-1 inhibitor compounds, a fluorometric plate assay was carried out to measure the half maximal in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen activator inhibitor 1(Homo sapiens (Human))
University Of Michigan

LigandPNGBDBM50132855(1-{3-[2-((1R,2S,5R)-2-Isopropyl-5-methyl-cyclohexy...)
Affinity DataIC50:  10nMAssay Description:Plasminogen Activator Inhibitor-1 (PAI-1) activity was determined using plasma clot lysis assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...)
Affinity DataIC50:  10nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen activator inhibitor 1(Homo sapiens (Human))
University Of Michigan

LigandPNGBDBM92485(CDE-066 | US9120744, CDE-066)
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:To determine the efficacy of various synthesized PAI-1 inhibitor compounds, a fluorometric plate assay was carried out to measure the half maximal in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290292(2-Oxo-4-(piperidin-4-yl)-1,2-dihydropyrimido[1,2-b...)
Affinity DataIC50:  10nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen activator inhibitor 1(Homo sapiens (Human))
University Of Michigan

LigandPNGBDBM50132862(4-{3-[2-((1R,2S,5R)-2-Isopropyl-5-methyl-cyclohexy...)
Affinity DataIC50:  10nMAssay Description:Plasminogen Activator Inhibitor-1 (PAI-1) activity was determined using plasma clot lysis assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen activator inhibitor 1(Homo sapiens (Human))
University Of Michigan

LigandPNGBDBM175528(US9120744, CDE-004)
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:To determine the efficacy of various synthesized PAI-1 inhibitor compounds, a fluorometric plate assay was carried out to measure the half maximal in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen activator inhibitor 1(Homo sapiens (Human))
University Of Michigan

LigandPNGBDBM175525(US9120744, CDE-001 (or 073))
Affinity DataIC50:  10nMpH: 7.8 T: 2°CAssay Description:To determine the efficacy of various synthesized PAI-1 inhibitor compounds, a fluorometric plate assay was carried out to measure the half maximal in...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetPlasminogen(Homo sapiens (Human))
Bristol-Myers Squibb Pharmaceutical Research Institute

Curated by ChEMBL
LigandPNGBDBM50124990(CHEMBL355376 | N-[4-Guanidino-1-(thiazole-2-carbon...)
Affinity DataIC50:  10nMAssay Description:Inhibitory activity against PlasminMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen(Rattus norvegicus)
RhôNe-Poulenc Rorer

Curated by ChEMBL
LigandPNGBDBM50081499(4-Hydroxy-3-[(S)-2-oxo-3-(thieno[2,3-c]pyridine-2-...)
Affinity DataIC50:  11nMAssay Description:Inhibitory activity against plasmin in ratMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290336(10-Chloro-8-methyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290334(9-Fluoro-10-phenyl-4-(piperidin-4-yl)pyrimido[1,2-...)
Affinity DataIC50:  11nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290324(4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290320(10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290314(10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290309((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290314(10-(2-Fluorophenyl)-4-(piperidin-4-yl)pyrimido[1,2...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290309((−)-trans-10-Ethoxy-4-(2-methylpiperidin-4-y...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290286(7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290324(4-(Piperidin-4-yl)-10-[2-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290286(7-Bromo-4-(piperidin-4-yl)pyrido[4′,3′...)
Affinity DataIC50:  13nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290320(10-Cyclopentyl-4-(piperidin-4-yl)pyrimido[1,2-b]in...)
Affinity DataIC50:  13nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290269(10-Bromo-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290313(10-Phenyl-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290312(4-(Piperidin-4-yl)-10-[4-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290307((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290313(10-Phenyl-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290329(10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...)
Affinity DataIC50:  14nMpH: 7.0Assay Description:The test compounds were dissolved in 1% acetic acid and further complemented with an equal volume of DMSO. The resulting stock solutions were seriall...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290307((−)-trans-10-Bromo-4-(2-methylpiperidin-4-yl...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290329(10-sec-Butyl-4-(piperidin-4-yl)pyrimido[1,2-b]inda...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen(Rattus norvegicus)
RhôNe-Poulenc Rorer

Curated by ChEMBL
LigandPNGBDBM50289436((S)-2-((R)-2-Acetylamino-3-phenyl-propionylamino)-...)
Affinity DataIC50:  14nMAssay Description:Inhibitory concentration of the compound against plasmin.More data for this Ligand-Target Pair
In DepthDetails Article
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290269(10-Bromo-4-(piperidin-4-yl)pyrimido[1,2-b]indazol-...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290312(4-(Piperidin-4-yl)-10-[4-(trifluoromethyl)phenyl]p...)
Affinity DataIC50:  14nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290315(4-(Piperidin-4-yl)-10-(pyridin-3-yl)pyrimido[1,2-b...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasminogen [101-181](Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM290262(10-Chloro-4-(piperidin-4-yl)pyrimido[1,2-b]indazol...)
Affinity DataIC50:  15nMAssay Description:The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 2784 total ) | Next | Last >>
Jump to: